Description:
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with
previously untreated CLL/SLL, as measured by progression free survival.
Title
- Brief Title: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
- Official Title: An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Clinical Trial IDs
- ORG STUDY ID:
BGB-3111-304
- SECONDARY ID:
2017-001551-31
- SECONDARY ID:
CTR20190416
- NCT ID:
NCT03336333
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
Drug | Synonyms | Arms |
---|
Zanubrutinib | BGB-3111, BRUKINSA | Cohort 1, Arm A: Zanubrutinib |
Bendamustine | Treanda, Ribomustin, and Levact | Cohort 1, Arm B: B+R |
Rituximab | Rituxan, MabThera | Cohort 1, Arm B: B+R |
Venetoclax | Venclexta, Venclyxto | Cohort 3, Arm D: Venetoclax + zanubrutinib |
Purpose
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with
previously untreated CLL/SLL, as measured by progression free survival.
Detailed Description
This is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine
plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia
or small lymphocytic lymphoma (CLL/SLL), including participants without del(17p) [Cohort 1]
and participants with del(17p) [Cohort 2 and Cohort 3]. Participants in Cohort 1 are
randomized 1:1 to zanubrutinib (Arm A) or bendamustine plus rituximab (Arm B). Randomization
will be stratified by age, Binet stage, immunoglobulin variable region heavy chain (IGHV)
mutational status, and geographic region. Participants in Cohort 2 will receive treatment
with zanubrutinib. Participants in Cohort 3 will receive treatment with zanubrutinib and
venetoclax.
Trial Arms
Name | Type | Description | Interventions |
---|
Cohort 1, Arm A: Zanubrutinib | Experimental | Participants will receive zanubrutinib until unacceptable toxicity or disease progression | |
Cohort 1, Arm B: B+R | Experimental | Participants will receive bendamustine plus rituximab for up to six 28-day cycles | |
Cohort 1a, Arm A (China only): Zanubrutinib | Experimental | Participants will receive zanubrutinib until unacceptable toxicity or disease progression | |
Cohort 1a, Arm B (China only): B + R | Experimental | Participants will receive bendamustine plus rituximab for up to six 28-day cycles | |
Cohort 2, Arm C: Zanubrutinib | Experimental | Participants will receive zanubrutinib until unacceptable toxicity or disease progression | |
Cohort 3, Arm D: Venetoclax + zanubrutinib | Experimental | Participants with del[17p] or TP53 mutation will receive venetoclax until unacceptable toxicity, disease progression, or for maximum of 24 cycles; Participants will also receive zanubrutinib for a minimum of 27 cycles, or until unacceptable toxicity or disease progression, whichever occurs first. | |
Eligibility Criteria
Key Inclusion Criteria:
- Unsuitable for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab
(FCR)
- Confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment.
- Measurable disease by imaging
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Life expectancy ≥ 6 months.
- Adequate bone marrow function.
- Adequate renal and hepatic function.
Key Exclusion Criteria:
- Previous systemic treatment for CLL/SLL.
- Requires ongoing need for corticosteroid treatment.
- Known prolymphocytic leukemia or history of or suspected Richter's transformation.
- Clinically significant cardiovascular disease.
- Prior malignancy within the past 3 years, except for curatively treated basal or
squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of
the cervix of breast, or localized Gleason score 6 prostate cancer.
- History of severe bleeding disorder.
- History of stroke or intracranial hemorrhage within 6 months before the first dose of
study drug.
- Severe or debilitating pulmonary disease.
- Inability to swallow capsules or disease affecting gastrointestinal function.
- Active infection requiring systemic treatment.
- Known central nervous system involvement by leukemia or lymphoma
- Underlying medical condition that will render the administration of study drug
hazardous or obscure interpretation of toxicity or AEs
- Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
infection.
- Major surgery ≤ 4 weeks prior to start of study treatment.
- Pregnant or nursing females.
- Vaccination with live vaccine within 35 days prior to the first dose of study drug.
- Ongoing alcohol or drug addiction
- Known hypersensitivity to zanubrutinib, bendamustine, rituximab, or venetoclax (as
applicable) or any other ingredients of the study drugs.
- Requires ongoing treatment with strong cytochrome P450 (CYP3A) inhibitor or inducer.
- Concurrent participation in another therapeutic clinical trial.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Cohort 1: Progression-free survival (PFS) between treatment groups (Zanubrutinib vs. B+R) as determined by independent central review (ICR). |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Cohort 1: Overall response rate (ORR) between treatment groups |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Pooled Cohort 1/1a: Overall response rate (ORR) between treatment groups |
Time Frame: | Up to 5 yearsl |
Safety Issue: | |
Description: | |
Measure: | Cohort 1: Overall survival (OS) between treatment groups |
Time Frame: | Up to 5 years. |
Safety Issue: | |
Description: | |
Measure: | Cohort 1: Duration of response (DOR) between treatment groups |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Pooled Cohort 1/1a: Duration of response (DOR) between treatment groups |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Cohort 1: Progression-free survival (PFS) between treatment groups determined by investigator assessment (IA). |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Pooled Cohort 1/1a: Progression-free survival (PFS) between treatment groups determined by investigator assessment (IA). |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Cohort 1: Patient-reported outcomes as assessed by the (European Quality Of Life 5D 5L) EQ-5D-5L questionnaire |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Cohort 1: Patient-reported outcomes as assessed by the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) questionnaire. |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Cohort 2: Overall response rate (ORR) |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Cohort 2: Progression-free survival (PFS) |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Cohort 2: Duration of response (DOR) |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | |
Measure: | Cohort 3: Overall response rate (ORR) |
Time Frame: | Up to 5 years. |
Safety Issue: | |
Description: | |
Measure: | Cohort 3: Progression-free survival (PFS) |
Time Frame: | Up to 5 years. |
Safety Issue: | |
Description: | |
Measure: | Cohort 3: Duration of response (DOR) |
Time Frame: | Up to 5 years. |
Safety Issue: | |
Description: | |
Measure: | Cohort 3: Rate of undetectable minimal residual disease (MRD4) |
Time Frame: | Up to 5 years. |
Safety Issue: | |
Description: | |
Measure: | Number of participants experiencing Adverse Events (AEs) |
Time Frame: | Up to 5 years. |
Safety Issue: | |
Description: | |
Measure: | Number of participants experiencing Serious Adverse Events (SAEs) |
Time Frame: | Up to 5 years. |
Safety Issue: | |
Description: | |
Measure: | Apparent rate of clearance of zanubrutinib from plasma (CL/F)CL/F |
Time Frame: | Predose up to 12 hours postdose |
Safety Issue: | |
Description: | |
Measure: | Cohort 1 Zanubrutinib only arms: Area-Under-Curve from time 0 to 12 hours postdose (AUC0-12) |
Time Frame: | Predose up to 12 hours postdose |
Safety Issue: | |
Description: | |
Measure: | Cohort 3: Area-Under-Curve from time 0 to 12 hours postdose (AUC0-12) of zanubrutinib |
Time Frame: | Predose up to 12 hours postdose |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | BeiGene |
Trial Keywords
- zanubrutinib
- BTK inhibitor
- bendamustine
- rituximab
- venetoclax
- BGB-3111
- Phase 3
Last Updated
August 13, 2021